Raphael Pharmaceutical (RAPH) EPS (Weighted Average and Diluted) (2021 - 2024)

Raphael Pharmaceutical has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting $0.02 for Q4 2024.

• EPS (Weighted Average and Diluted) for Q4 2024 came in at $0.02, up 149.51% year-over-year; the trailing twelve-month figure through Dec 2024 was $0.07 (up 773.27% YoY), and the FY2025 annual result was $0.07, down 12.5% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.02 for Q4 2024 at Raphael Pharmaceutical, up from $0.01 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.1 in Q3 2022 to a low of $0.01 in Q4 2023.
• The 4-year median for EPS (Weighted Average and Diluted) is $0.03 (2021), against an average of $0.04.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 233.33% in 2022 and sank 88.55% in 2023, its largest moves.
• Raphael Pharmaceutical's EPS (Weighted Average and Diluted) stood at $0.06 in 2021, then rose by 16.67% to $0.07 in 2022, then tumbled by 88.55% to $0.01 in 2023, then soared by 149.51% to $0.02 in 2024.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.02 (Q4 2024), $0.01 (Q3 2024), and $0.01 (Q2 2024), per Business Quant data.